LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,095
تعداد مقالات10,042
تعداد مشاهده مقاله28,023,798
تعداد دریافت فایل اصل مقاله7,816,027
Rezapour, Aziz, Javan-Noughabi, Javad, Faramarzi, Ahmad, Harati Khalilabad, Touraj, Vahedi, Sajjad, Teymourizad, Abedin. (1396). Quality of Life in Breast Cancer Patients using Neoadjuvant AC (Doxorubicin and Cyclophosphamide) in Comparison with PG (Paclitaxel and Gemcitabine) Therapy. سامانه مدیریت نشریات علمی, 9(1), 41-47. doi: 10.30476/mejc.2018.42103
Aziz Rezapour; Javad Javan-Noughabi; Ahmad Faramarzi; Touraj Harati Khalilabad; Sajjad Vahedi; Abedin Teymourizad. "Quality of Life in Breast Cancer Patients using Neoadjuvant AC (Doxorubicin and Cyclophosphamide) in Comparison with PG (Paclitaxel and Gemcitabine) Therapy". سامانه مدیریت نشریات علمی, 9, 1, 1396, 41-47. doi: 10.30476/mejc.2018.42103
Rezapour, Aziz, Javan-Noughabi, Javad, Faramarzi, Ahmad, Harati Khalilabad, Touraj, Vahedi, Sajjad, Teymourizad, Abedin. (1396). 'Quality of Life in Breast Cancer Patients using Neoadjuvant AC (Doxorubicin and Cyclophosphamide) in Comparison with PG (Paclitaxel and Gemcitabine) Therapy', سامانه مدیریت نشریات علمی, 9(1), pp. 41-47. doi: 10.30476/mejc.2018.42103
Rezapour, Aziz, Javan-Noughabi, Javad, Faramarzi, Ahmad, Harati Khalilabad, Touraj, Vahedi, Sajjad, Teymourizad, Abedin. Quality of Life in Breast Cancer Patients using Neoadjuvant AC (Doxorubicin and Cyclophosphamide) in Comparison with PG (Paclitaxel and Gemcitabine) Therapy. سامانه مدیریت نشریات علمی, 1396; 9(1): 41-47. doi: 10.30476/mejc.2018.42103

Quality of Life in Breast Cancer Patients using Neoadjuvant AC (Doxorubicin and Cyclophosphamide) in Comparison with PG (Paclitaxel and Gemcitabine) Therapy

Middle East Journal of Cancer
مقاله 7، دوره 9، شماره 1، فروردین 2018، صفحه 41-47    اصل مقاله (147.47 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2018.42103
نویسندگان
Aziz Rezapour1؛ Javad Javan-Noughabi* 2؛ Ahmad Faramarzi3؛ Touraj Harati Khalilabad2؛ Sajjad Vahedi2؛ Abedin Teymourizad2
1Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
2Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
3Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
چکیده
Background: Quality of life has become a part of the evaluation criteria for cancer therapy. The aim of this study was to evaluate the quality of life in breast cancer patients under chemotherapy regimens that contained doxorubicin and cyclophosphamide (AC) compared to paclitaxel and gemcitabine (PG).Methods: This cohort study evaluated 100 women with breast cancer treated by doxorubicin and cyclophosphamide or gemcitabine and paclitaxel regimens. We used the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 to assess health related quality of life at the beginning and end of chemotherapy. Data were analyzed by the independent t-test at a significance level of 0.05.Results: Most of the 100 patients were married (68%), aged 41-50 years (36%), non-college educated (76%), and had insurance (97%). The mean quality of life scores at the first session of chemotherapy and prior to the onset of treatment-related adverse events were 71.33 for the doxorubicin and cyclophosphamide groups and 71.15 for the gemcitabine and paclitaxel groups. Analysis of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 at the last chemotherapy session showed that the quality of life in both groups deteriorated as a result of side effects. The mean of quality of life scores at the first session of chemotherapy were 66.49 for the doxorubicin and cyclophosphamide group and 59.99 for the gemcitabine and paclitaxel group.Conclusion: Strategies to improve the emotional and role functions of the patients who undergo treatment should be given priority. Financial difficulties faced by breast cancer patients should be addressed from a policy making level at the initiating health financing system.
آمار
تعداد مشاهده مقاله: 2,668
تعداد دریافت فایل اصل مقاله: 665


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب